Business Context and Reporting Period
This Form 8-K Current Report from HEALTHEQUITY, INC. covers events occurring on June 27, 2024, specifically the Company's 2024 Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes and the approval of a new equity incentive plan.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder actions. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's most recent Form 10-K or 10-Q for financial statements.
Material Changes and Shareholder Actions
At the Annual Meeting, stockholders approved four key proposals:
- Director Elections: All ten director nominees were elected to serve until the 2025 Annual Meeting. Vote counts ranged from approximately 76.9 million to 78.3 million "For" votes.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending January 31, 2025.
- Executive Compensation: The fiscal 2024 compensation for named executive officers was approved on a non-binding, advisory basis.
- Equity Incentive Plan: The HealthEquity, Inc. 2024 Equity Incentive Plan was approved. This plan replaces the 2014 Equity Incentive Plan, under which no further awards will be made.
Guidance, Outlook, and Plan Details
The filing provides specific details regarding the newly approved 2024 Equity Incentive Plan:
- Share Reserve: The aggregate number of shares reserved for issuance under the 2024 Plan is 4,085,000.
- Eligibility: Awards are available to employees, consultants, and non-employee directors.
- Award Types: The plan permits incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance stock awards, and other stock-based awards.
- Administration: The plan is administered by the Talent, Compensation and Culture Committee of the Board.
The filing does not contain forward-looking financial guidance, management commentary on market conditions, or specific risk factors beyond standard corporate governance disclosures.
Investor Verification Checklist
- Verify the full text of the 2024 Equity Incentive Plan (Exhibit 10.1) to understand vesting schedules and performance metrics.
- Review the definitive proxy statement filed on May 17, 2024, for detailed biographies of the newly elected directors.
- Confirm the impact of the new equity plan on potential future dilution relative to the 4,085,000 share reserve.
- Check subsequent filings for the Company's fiscal year-end financial results, as this 8-K contains no financial data.